Michael P. Kosty
Scripps Health
CancerPathologyChemotherapyFamily medicineMedicine
What is this?
Publications 57
#1Shannon Fortin Ensign (Scripps Research Institute)
#2Kathryn Bollin (Scripps Health)H-Index: 1
Last. Christopher M. Uchiyama (Scripps Health)
view all 6 authors...
#1J. Rothenstein (Durham University)H-Index: 1
#2Alexander I. SpiraH-Index: 27
Last. C.A. ThomasH-Index: 1
view all 15 authors...
1 CitationsSource
Purpose:Advanced practice providers (APPs, which include nurse practitioners [NPs] and physician assistants [PAs]) are integral members of oncology teams. This study aims first to identify all oncology APPs and, second, to understand personal and practice characteristics (including compensation) of those APPs.Methods:We identified APPs who practice oncology from membership and claims data. We surveyed 3,055 APPs about their roles in clinical care.Results:We identified at least 5,350 APPs in onco...
4 CitationsSource
#2Konstantinos N. Syrigos (UoA: National and Kapodistrian University of Athens)H-Index: 40
Last. Louis Fehrenbacher (KP: Kaiser Permanente)H-Index: 56
view all 17 authors...
#1Munveer S. Bhangoo (Scripps Health)H-Index: 4
#2Brian Cheng (Scripps Health)H-Index: 1
Last. Michael P. Kosty (Scripps Health)H-Index: 23
view all 5 authors...
1 CitationsSource
#1J. von PawelH-Index: 60
Last. Louis Fehrenbacher (KP: Kaiser Permanente)H-Index: 56
view all 17 authors...
4 CitationsSource
#1Diego CortinovisH-Index: 18
#2J. von PawelH-Index: 60
Last. David R. GandaraH-Index: 76
view all 17 authors...
1 CitationsSource
Metastatic lung cancer is often rapidly fatal even with cytotoxic chemotherapy treatment. The interaction of malignant cells with the immune system at the level of checkpoint proteins on T cells, has proven to be an effective novel target. Several so-called checkpoint inhibitors have since been developed and demonstrate benefit after chemotherapy failure, and in some cases, show benefit as first line treatment for advanced or metastatic lung cancer. This review will highlight the notable studies...
#2Michael P. Kosty (Scripps Health)H-Index: 23
Last. Gunta PurkalneH-Index: 4
view all 11 authors...
2 CitationsSource
#1Michael P. KostyH-Index: 23
#2Priya KumarH-Index: 10
Last. Thomas J. LynchH-Index: 68
view all 8 authors...
e19045 Background: BV (Avastin), an anti-VEGF monoclonal antibody, prolongs progression-free and overall survival in advanced NSCLC pts. Severe (≥grade 3) pulmonary hemorrhage (sPH) is a rare but serious event that has been associated with BV-based therapy in phase 3 trials (rate of 2–4%). Potential risk factors include squamous histology, prior history of hemoptysis, and presence of tumor cavitation. Rates of baseline (BL) cavitation in NSCLC pts and development of cavitation on BV therapy are ...